These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37525039)

  • 1. Omics Analyses in a Neural Stem Cell Model of Familial Parkinson's Disease.
    Notopoulou S; Gkekas I; Petrakis S
    Adv Exp Med Biol; 2023; 1423():149-160. PubMed ID: 37525039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication.
    Flierl A; Oliveira LM; Falomir-Lockhart LJ; Mak SK; Hesley J; Soldner F; Arndt-Jovin DJ; Jaenisch R; Langston JW; Jovin TM; Schüle B
    PLoS One; 2014; 9(11):e112413. PubMed ID: 25390032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of α-Synuclein and Disease-Associated Factors in
    Suzuki M; Sango K; Nagai Y
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Signs of Molecular Defects in iPSC-Derived Neural Stems Cells from Patients with Familial Parkinson's Disease.
    Akrioti E; Karamitros T; Gkaravelas P; Kouroupi G; Matsas R; Taoufik E
    Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons.
    Zambon F; Cherubini M; Fernandes HJR; Lang C; Ryan BJ; Volpato V; Bengoa-Vergniory N; Vingill S; Attar M; Booth HDE; Haenseler W; Vowles J; Bowden R; Webber C; Cowley SA; Wade-Martins R
    Hum Mol Genet; 2019 Jun; 28(12):2001-2013. PubMed ID: 30753527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease.
    Sakai R; Suzuki M; Ueyama M; Takeuchi T; Minakawa EN; Hayakawa H; Baba K; Mochizuki H; Nagai Y
    PLoS One; 2019; 14(6):e0218261. PubMed ID: 31242217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The central theme of Parkinson's disease: α-synuclein.
    Ozansoy M; Başak AN
    Mol Neurobiol; 2013 Apr; 47(2):460-5. PubMed ID: 23180276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
    Yasuda T; Mochizuki H
    Apoptosis; 2010 Nov; 15(11):1312-21. PubMed ID: 20221696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UBA52 Is Crucial in HSP90 Ubiquitylation and Neurodegenerative Signaling during Early Phase of Parkinson's Disease.
    Tiwari S; Singh A; Gupta P; Singh S
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of gene-corrected iPSC line from Parkinson's disease patient iPSC line with alpha-SNCA A53T mutation.
    Lee SY; Jeong S; Kim J; Chung SK
    Stem Cell Res; 2018 Jul; 30():145-149. PubMed ID: 29906669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease
    Yoon HH; Ye S; Lim S; Jo A; Lee H; Hong F; Lee SE; Oh SJ; Kim NR; Kim K; Kim BJ; Kim H; Lee CJ; Nam MH; Hur JW; Jeon SR
    CRISPR J; 2022 Feb; 5(1):95-108. PubMed ID: 35191750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.
    Wilson H; Dervenoulas G; Pagano G; Koros C; Yousaf T; Picillo M; Polychronis S; Simitsi A; Giordano B; Chappell Z; Corcoran B; Stamelou M; Gunn RN; Pellecchia MT; Rabiner EA; Barone P; Stefanis L; Politis M
    Lancet Neurol; 2019 Aug; 18(8):748-759. PubMed ID: 31229470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retina as a Model to Study In Vivo Transmission of α-Synuclein in the A53T Mouse Model of Parkinson's Disease.
    Mammadova N; Baron T; Verchère J; Greenlee JJ; Greenlee MHW
    Methods Mol Biol; 2021; 2224():75-85. PubMed ID: 33606207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson's disease.
    Kouroupi G; Taoufik E; Vlachos IS; Tsioras K; Antoniou N; Papastefanaki F; Chroni-Tzartou D; Wrasidlo W; Bohl D; Stellas D; Politis PK; Vekrellis K; Papadimitriou D; Stefanis L; Bregestovski P; Hatzigeorgiou AG; Masliah E; Matsas R
    Proc Natl Acad Sci U S A; 2017 May; 114(18):E3679-E3688. PubMed ID: 28416701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling Parkinson's disease with induced pluripotent stem cells harboring α-synuclein mutations.
    Singh Dolt K; Hammachi F; Kunath T
    Brain Pathol; 2017 Jul; 27(4):545-551. PubMed ID: 28585381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes.
    Teravskis PJ; Covelo A; Miller EC; Singh B; Martell-Martínez HA; Benneyworth MA; Gallardo C; Oxnard BR; Araque A; Lee MK; Liao D
    J Neurosci; 2018 Nov; 38(45):9754-9767. PubMed ID: 30249789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
    Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ
    Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease and the gut: Models of an emerging relationship.
    Bindas AJ; Kulkarni S; Koppes RA; Koppes AN
    Acta Biomater; 2021 Sep; 132():325-344. PubMed ID: 33857691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.